Therapeutic Indications

Blinatumomab is indicated for:

B-precursor acute lymphoblastic leukaemia (ALL), Philadelphia chromosome negative, CD19 positive

Irrespective of gender only Children (1 year - 12 years old)

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Blinatumomab is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 5-15 mcg/m2 once a day

B-precursor acute lymphoblastic leukaemia (ALL), Philadelphia chromosome negative, CD19 positive

Irrespective of gender only Adolescents (12 years - 18 years old) , Adults (18 - 65 years old)

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Blinatumomab is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 9-28 mcg once a day

Contraindications

Active ingredient Blinatumomab is contraindicated in the following cases:

Lactation

No gender/age discrimination

It is unknown whether blinatumomab or metabolites are excreted in human milk. Based on its pharmacological properties, a risk to the suckling child cannot be excluded. Consequently, as a precautionary measure, breast-feeding is contraindicated during and for at least 48 hours after treatment with blinatumomab.